Your AI-Trained Oncology Knowledge Connection!

Hans Jochen Wilke, MD

home / authors / hans-jochen-wilke-md

Articles

Oral Fluoropyrimidine-Based Combination Therapy in Gastrointestinal Cancer

January 2nd 2001

Significant emphasis has been placed recently on designing more effective fluorouracil (5-FU)-based combination protocols for gastrointestinal cancer. Promising results were seen with 5-FU/leucovorin in combination with

Developments in the Treatment of Gastric Cancer in Europe

Claus Henning Köhne, MD;Jacques A. Wils, MD;Hans Jochen Wilke, MD

December 3rd 2000

Metastatic gastric cancer is a relatively chemosensitive disease. With current regimens, 25% to 40% of patients can be expected to respond, and median survival of 6 to 8 months is

Fluorouracil-Based Combinations in the Treatment of Metastatic Breast Cancer

Ute Klaassen, MD;Hans Jochen Wilke, MD

January 1st 1998

Although combination chemotherapy regimens may prolong survival for selected patients with metastatic breast cancer, few, if any, are cured. The standard regimens used in treatment, eg, CMF (cyclophosphamide,

Infusional 5-FU, Folinic Acid, Paclitaxel, and Cisplatin for Metastatic

Ute Klaassen, MD;Hans Jochen Wilke, MD;Christian Müller, MD;David Borquez, MD;Michael Korn, MD;Klaus Diergarten, MD;Siegfried Seeber, MD, PhD

April 1st 1997

Our phase II study results demonstrating high efficacy and low toxicity for a weekly schedule of high-dose, 24-hour infusional 5-fluorouracil(5-FU)/folinic acid (HD5-FU/FA) in intensively pretreated patients with metastatic